Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, an inhibitor of hepatitis C virus (HCV) NS5A, in healthy subjects and subjects chronically infected with HCV genotype 1
about
Inclusion of placebos and blinding for ascending dose first-in-human studies and other underpowered phase 1 studies has not been justified and on balance is not usefulHepatitis C virus NS5A inhibitors and drug resistance mutations.Direct-acting antivirals for chronic hepatitis C.A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-inVirology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845.Preclinical characterization of GSK2336805, a novel inhibitor of hepatitis C virus replication that selects for resistance in NS5APharmacokinetics of hepatitis C virus NS5A inhibitor JNJ-56914845 (GSK2336805) in subjects with hepatic impairment.Effects of omeprazole and ritonavir on absorption and elimination of the hepatitis C virus NS5A inhibitor GSK2336805 in healthy adults.Global elimination of hepatitis C virus infection: Progresses and the remaining challenges.Direct-acting antivirals for chronic hepatitis C
P2860
Q26995810-DA8DBE2F-BDA3-4DC6-9DB4-41F170B5BC6DQ34411617-E9EACC75-5F31-4015-9CFE-033E85EF98C2Q34557595-E5C93A58-1D6E-49C6-A3FF-884E49D23D8CQ38443343-C8420092-9BD0-45A4-A6EE-FA8A2C3E6F03Q38751552-E0A6F146-D1E8-45BC-91E8-49CD51C1D12EQ41907539-26CF1C65-A9C3-4A36-867F-70E469A7E2C6Q42149746-75E8C693-8C8F-414D-BEAC-1A7BB24CEC54Q42195777-8E404574-0065-4D4C-8FA3-5599AF097B1CQ47274792-465BC954-0F92-4623-82A3-C10E7508C70DQ57389418-553CF61D-1A5D-47D3-AFE3-CB73C767EE93
P2860
Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, an inhibitor of hepatitis C virus (HCV) NS5A, in healthy subjects and subjects chronically infected with HCV genotype 1
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Safety, tolerability, pharmaco ...... y infected with HCV genotype 1
@en
Safety, tolerability, pharmaco ...... infected with HCV genotype 1.
@nl
type
label
Safety, tolerability, pharmaco ...... y infected with HCV genotype 1
@en
Safety, tolerability, pharmaco ...... infected with HCV genotype 1.
@nl
prefLabel
Safety, tolerability, pharmaco ...... y infected with HCV genotype 1
@en
Safety, tolerability, pharmaco ...... infected with HCV genotype 1.
@nl
P2093
P2860
P356
P1476
Safety, tolerability, pharmaco ...... y infected with HCV genotype 1
@en
P2093
C L Moseley
D A Wilfret
K K Adkison
M de Serres
P2860
P304
P356
10.1128/AAC.00910-13
P407
P577
2013-07-29T00:00:00Z